局部进展期胃癌新辅助治疗的价值、问题及对策OA北大核心CSTPCD

Neoadjuvant therapy for locally advanced gastric cancer(LAGC)has become a normalized treatment mode and has been recommended by gastric cancer treatment guidelines in Europe,America,Japan,the Republic of Korea,and China.Although the safety,effectiveness,and long-term outcomes of neoadjuvant therapy for gastric cancer have been confirmed by multiple studies,there are many problems in case selection,chemotherapy resistance,chemotherapy regimen optimization,efficacy evaluation system,and laparoscopic surgery.In addi-tion,there is a lack of specific molecular markers for the effica-cy and long-term prognosis of neoadjuvant therapy,which to some extent poses challenges to the effectiveness and long-term prognosis of LAGC neoadjuvant therapy.Although neoad-juvant therapy faces many controversies,the in depth develop-ment of large scale clinical studies,new drug research,gastric cancer related mechanism studies,and the improvement of effi-cacy evaluation systems are expected to further enhance the ef-fectiveness of neoadjuvant therapy.Its important position in the comprehensive system of individualized and precise treat-ment of LAGC will be further strengthened.